Docoh
Loading...

AMYT Amryt Pharma

Filed: 5 May 21, 9:40am

Exhibit 99.1

 

Amryt Reports Record Q1 2021 Financial and Operating Results

 

8.7% YoY revenue growth in the quarter to $48.4M

 

16.5% YoY underlying revenue growth excluding the impact of a LATAM periodic order in Q1 2020

 

5th consecutive quarter of positive EBITDA generation

 

National reimbursement achieved for metreleptin in England, Wales and France

 

Regulatory submissions for Oleogel-S101 (Filsuvez®) made to the FDA and EMA

 

Raising FY 2021 revenue guidance to $205M - $210M

 

Today announced proposed acquisition of Chiasma, Inc. (Nasdaq: CHMA)

 

Conference call and webcast today at 0830 EDT / 1330 BST

 

DUBLIN, Ireland, and Boston MA, May 5, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today provides a business update and announces unaudited financial results for the first quarter ended March 31, 2021.

 

Joe Wiley, CEO of Amryt Pharma, commented: “I am very pleased with today’s very strong results for Q1 which represent a 13.9% increase in revenues on Q4 and which demonstrate the continued positive momentum and growth we are experiencing in our business across our two commercial products globally. Q1 was extremely busy and we delivered a number of commercial and regulatory successes during the quarter. Our two commercial products, metreleptin and lomitapide, continue to deliver solid growth across a host of metrics including revenue, EBITDA growth, cash generation and market expansion. Our EBITDA has increased 115% compared to the same quarter in 2020.

 

We also achieved a number of positive reimbursement decisions in the quarter, notably for metreleptin in England, Wales and France. On the development front, we made regulatory submissions to both the FDA and EMA for Oleogel-S10 and we continue to work with the respective agencies as we progress towards potential approval and prepare for launch. If approved, we have the commercial team, systems and infrastructure in place to both grow our existing products and to leverage these capabilities to launch Oleogel-S10.

 

Given the strong performance of the business during the quarter, we are now increasing our revenue guidance for 2021 from $200-$205 million to $205-$210 million excluding any potential contribution from the proposed Chiasma transaction, which represents growth of between 12% - 15% on 2020.

 

Furthermore, we today announced the proposed acquisition of Chiasma, Inc. (Nasdaq: CHMA). We believe this transformational deal can pave a path to a combined potential $1BN peak revenue for Amryt.”

 

 1 

 

Q1 2021 & Recent Business Highlights:

 

·Submitted a New Drug Application to the FDA for Oleogel-S10
·Marketing Authorisation Application (MAA) accepted by the EMA for Oleogel-S10
·Reimbursement approval for metreleptin in England, Wales and France
·Positive feedback from the FDA on the path forward for metreleptin indication in partial lipodystrophy (PL) – Phase 3 planned for Q4 2021
·Positive results reported from an investigator sponsored study of lomitapide in familial chylomicronaemia syndrome (FCS)
·Multi-regional distribution and product agreements signed with Medison in Canada and in Israel
·Announced proposed acquisition of Chiasma, Inc. (Nasdaq: CHMA)

 

 

Q1 Commercial Product Performance:

 

 Q1 2021 (unaudited)
 USEMEAOtherTotal
 US$’000US$’000US$’000US$’000
Metreleptin16,23912,97175029,960
Lomitapide8,3247,4402,42018,184
Other-22365288
Total revenue24,56320,6343,23548,432

 

 Q1 2020 (unaudited)
 USEMEAOtherTotal
 US$’000US$’000US$’000US$’000
Metreleptin14,9148,6283,38526,927
Lomitapide9,4705,2332,71817,421
Other-226-226
Total revenue24,38414,0876,10344,574

 

·8.7% revenue growth in Q1 2021 to $48.4M (Q1 2020: $44.6M)
·16.5% underlying YoY revenue growth excluding a periodic LATAM order in Q1 2020 that did not occur in Q1 2021. A significant order has now been received and will be booked in Q2 2021.
·11.3% increase in metreleptin revenues YoY to $30.0M in Q1 2021 (Q1 2020: $26.9M). Excluding impact of periodic LATAM ordering, metreleptin revenues grew 25.3% in Q1.
·US accounted for 54.2% of global metreleptin revenues and EMEA accounted for 43.3% in Q1 2021. EMEA metreleptin revenues increased by 50.3% in Q1 2021 versus Q1 2020.
·4.4% increase in lomitapide revenues to $18.2M in Q1 (Q1 2020: $17.4M)
·US accounted for 45.8% of global lomitapide revenues and EMEA accounted for 40.9% in Q1 2021. EMEA lomitapide revenues increased by 42.2% in Q1 2021 versus Q1 2020.
·13.9% QoQ revenue growth in Q1 2021 versus Q4 2020 ($42.5M)

 

Q1 Financial Highlights:

·$3.4M operating loss before finance expense for Q1 2021 (Q1 2020: $17.0M). Excluding non-cash items and share based compensation expenses, this resulted in EBITDA3 of $9.9M (Q1 2020: $4.6M).
·Cash of $118.6M at March 31, 2021 (Dec 31, 2020: $118.8M)
·Legacy fines levied on Aegerion were fully discharged in Q1 2021

 

1For the purposes of this announcement, we use the name Oleogel-S10. Filsuvez® has been selected as the brand name for the product but please note, Amryt does not, as yet, have regulatory approval for Filsuvez® to treat EB.

 

 2 

 

 

 

IFRS and non-GAAP adjusted Q1 2021 results:

 

US$M

Q1 2020

(unaudited)

 

Q1 2021

(unaudited)

Q1 2021

Non-cash adjustments2

Q1 2021 Non-GAAP Adjusted
Revenue44.648.4-48.4
Gross profit12.024.911.736.7
R&D expenses(8.9)(8.9)-(8.9)
SG&A expenses(18.4)(18.2)0.3(17.9)
Acquisition & severance related costs(0.9)---
Share based compensation expenses(0.8)(1.3)1.3-
Operating (loss) / profit before finance expense(17.0)(3.4)13.3

9.93

 

 

The Q1 operating loss of $3.4M includes the impact of non-cash items including amortisation, depreciation and the impact of share-based compensation expenses. Adjusting for these non-cash items, the Company delivered $9.9M of EBITDA3 for the quarter.

 

2Non-cash items include amortisation of the acquired metreleptin and lomitapide intangible assets ($10.7M), amortisation of the inventory fair value step-up that was acquired at the acquisition date ($1.0M), depreciation and amortisation ($0.3M) and share based compensation expenses ($1.3M).
3EBITDA is earnings before interest, tax, depreciation, amortisation and share based compensation expenses. To supplement Amryt's financial results presented in accordance with IFRS generally accepted accounting principles, the Company uses EBITDA as a key measure of company performance as the Company believes that this measure is most reflective of the operational profitability or loss of the Company and provides management and investors with useful supplementary information which can enhance their ability to evaluate the operating performance of the business. EBITDA, as measured by the Company, is not meant to be considered in isolation or as a substitute to operating profit / loss attributable to Amryt and should be read in conjunction with the Company's condensed consolidated financial statements prepared in accordance with IFRS.

 

Post-Period End Events: 

The company earlier today announced that it has signed a definitive agreement to acquire Chiasma, Inc. (Nasdaq: CHMA). The combined Company will be a global leader in rare and orphan diseases with three on-market commercial products, a global commercial and operational footprint and a significant development pipeline of therapies with the financial flexibility to execute its growth plans.

 

Guidance & Outlook:

Amryt issued FY 2021 revenue guidance on March 4, 2021 indicating that FY 2021 revenues were expected to be in the range of $200M-$205M. Given the continued strong performance of the Company’s commercial products, the board is now increasing FY 2021 revenue guidance to a range of $205M-$210M excluding any potential contribution from the proposed Chiasma transaction, which represents growth of 12-15% versus FY 2020.

 

Conference Call & Webcast:

Amryt will host a conference call and webcast for analysts and investors on May 5 at 0830 EDT/1330 BST. Webcast Player URL: https://edge.media-server.com/mmc/p/hdecnon9

 

Telephone Dial in details:

United States+1 646 787 1226
United Kingdom+44 (0) 203 009 5709
Ireland+353 (1) 506 0626
Confirmation Code8698345

 

 3 

 

About Amryt

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.

 

Amryt’s commercial business comprises two orphan disease products – metreleptin (Myalept®/ Myalepta®) and lomitapide (Juxtapid®/ Lojuxta®).

 

Myalept®/Myalepta® (metreleptin) is approved in the US (under the trade name Myalept®) as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in the EU (under the trade name Myalepta®) as an adjunct to diet for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. For additional information, please follow this link.

 

Juxtapid®/Lojuxta® (lomitapide) is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia ("HoFH") in the US, Canada, Colombia, Argentina and Japan (under the trade name Juxtapid®) and in the EU, Israel and Brazil (under the trade name Lojuxta®). For additional information, please follow this link.

 

Amryt's lead development candidate, Oleogel-S10 (Filsuvez®) is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (“EB”), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. Filsuvez® has been selected as the brand name for Oleogel-S10. The product does not currently have regulatory approval to treat EB.

 

Amryt’s pre-clinical gene therapy platform, AP103, offers a potential treatment for patients with Dystrophic EB, and is also potentially relevant to other genetic disorders. 

 

For more information on Amryt, including products, please visit www.amrytpharma.com.

 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014. The person making this notification on behalf of Amryt is Rory Nealon, CFO/COO and Company Secretary.

 

Financial Advisors

 

Shore Capital (Edward Mansfield, Daniel Bush, John More) are NOMAD and Joint Broker to Amryt in the UK. Stifel (Ben Maddison) are Joint Broker to the company in the UK.

 

Forward-Looking Statements

 

This press release may contain forward-looking statements containing the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Amryt's present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond each of Amryt's ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt's ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information that may arise in connection with it. Such forward-looking statements reflect the Company’s current beliefs and assumptions and are based on information currently available to management.

 

 4 

 

Contacts

 

Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200, ir@amrytpharma.com

 

Edward Mansfield, Shore Capital, NOMAD, +44 (0) 207 468 7906, edward.mansfield@shorecap.co.uk

 

Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564, tim@lifesciadvisors.com

 

Amber Fennell, Consilium Strategic Communications, +44 (0) 203 709 5700

 

 

 

 5 

 

 

Amryt Pharma plc
Condensed Consolidated Statement of Comprehensive Loss

    

Three Months Ended

March 31,

  Note 

2021

(unaudited)

 

2020

(unaudited)

     US$’000   US$’000 
Revenue 3  48,432   44,574 
Cost of sales    (23,489)  (32,620)
Gross profit    24,943   11,954 
Research and development expenses    (8,916)  (8,934)
Selling, general and administrative expenses    (18,156)  (18,406)
Restructuring and acquisition costs 5     (853)
Share based payment expenses 4  (1,263)  (745)
Operating loss before finance expense    (3,392)  (16,984)
Non-cash change in fair value of contingent consideration 5  (2,874)  (2,906)
Non-cash contingent value rights finance expense 5  (1,763)  (1,448)
Net finance expense - other    (7,898)  (9,416)
Loss on ordinary activities before taxation    (15,927)  (30,754)
Tax (charge)/credit on loss on ordinary activities    (610)  1,857 
Loss for the period attributable to the equity holders of the Company    (16,537)  (28,897)
Exchange translation differences which may be reclassified through profit or loss    2,547   (13)
Total other comprehensive income/(loss)    2,547   (13)
Total comprehensive loss for the period attributable to the equity holders of the Company    (13,990)  (28,910)
           
Loss per share          
Loss per share - basic and diluted, attributable to ordinary equity holders of the parent (US$) 6  (0.09)  (0.19)

 

 6 

 

 

Amryt Pharma plc
Condensed Consolidated Statement of Financial Position

    As at,
  Note 

March 31, 2021

(unaudited)

 

December 31, 2020

(audited)

     US$’000   US$’000 
Assets          
Non-current assets          
Goodwill 7  19,131   19,131 
Intangible assets 7  292,315   305,369 
Property, plant and equipment    7,156   7,574 
Other non-current assets    1,484   1,542 
Total non-current assets    320,086   333,616 
Current assets          
Trade and other receivables 8  43,963   43,185 
Inventories    39,371   40,992 
Cash and cash equivalents, including restricted cash 9  118,551   118,798 
Total current assets    201,885   202,975 
Total assets    521,971   536,591 
           
Equity and liabilities          
Equity attributable to owners of the parent          
Share capital 10  13,899   13,851 
Share premium 10  51,596   51,408 
Other reserves 10  241,011   236,488 
Accumulated deficit    (252,142)  (235,605)
Total equity    54,364   66,142 
Non-current liabilities          
Contingent consideration and contingent value rights 5  149,064   148,323 
Deferred tax liability    6,753   6,612 
Long term loan 11  88,769   87,302 
Convertible notes 12  102,216   101,086 
Provisions and other liabilities 13  26,649   25,951 
Total non-current liabilities    373,451   369,274 
Current liabilities          
Trade and other payables    87,189   90,236 
Provisions and other liabilities 13  6,967   10,939 
Total current liabilities    94,156   101,175 
Total liabilities    467,607   470,449 
Total equity and liabilities    521,971   536,591 

 

 7 

 

Amryt Pharma plc
Condensed Consolidated Statement of Cash Flows

    

Three months ended

March 31,

  Note 

2021

(unaudited)

 

2020

(unaudited)

     US$’000   US$’000 
Cash flows from operating activities          
Loss on ordinary activities after taxation    (16,537)  (28,897)
Net finance expense - other    7,898   9,416 
Depreciation and amortization    11,058   11,241 
Amortization of inventory fair value step-up    951   9,503 
Share based payment expenses 4  1,263   745 
Non-cash change in fair value of contingent consideration 5  2,874   2,906 
Non-cash contingent value rights finance expense 5  1,763   1,448 
Deferred taxation credit    141   (1,576)
Movements in working capital and other adjustments:          
Change in trade and other receivables 8  (778)  (4,792)
Change in trade and other payables    (3,483)  9,416 
Change in provision and other liabilities 13  (3,138)  (3,435)
Change in inventories    670   216 
Change in non-current assets    58   (4)
Net cash flow from operating activities    2,740   6,187 
           
Cash flow from investing activities          
Payments for property, plant and equipment    (71)  (79)
Payments for intangible assets    (416)   
Deposit interest received    1   66 
Net cash flow used in investing activities    (486)  (13)
           
Cash flow from financing activities          
Net costs from issue of equity instruments    (175)   
Interest paid    (1,418)  (1,506)
Payment of leases    (263)   
Net cash flow from financing activities    (1,856)  (1,506)
           
Exchange and other movements    (645)  (3,830)
           
Net change in cash and cash equivalents    (247)  838 
Cash and cash equivalents at beginning of the period    118,798   67,229 
Restricted cash at end of the period 9  29   1,093 
Cash at bank available on demand at end of the period 9  118,522   66,974 
Total cash and cash equivalents at end of the period 9  118,551   68,067 

 8 

 

 

Amryt Pharma plc
Condensed Consolidated Statement of Changes in Equity

For the period ended March 31, 2021

(unaudited)

  Note Share capital Share premium Warrant reserve Treasury shares Share based payment reserve Merger reserve Reverse acquisition reserve Equity component of convertible notes Other distributable reserves Currency translation reserve Accumulated deficit Total
       US$’000   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000 
Balance at January 1, 2021 (audited)      13,851   51,408   14,762   (7,421)  7,860   42,627   (73,914)  29,210   217,634   5,730   (235,605)  66,142 
Loss for the period                                    (16,537)  (16,537)
Foreign exchange translation reserve                                 2,547      2,547 
Total comprehensive loss                                 2,547   (16,537)  (13,990)
Transactions with owners                                                    
Issue of treasury shares in exchange for warrants  10   23   99      439                        561 
Issue of treasury shares for share options exercised  10   25   89      465   (191)                    388 
Share based payment expense  4               1,263                     1,263 
Share based payment expense – Lapsed                                        
Total transactions with owners      48   188      904   1,072                     2,212 
Balance at March 31, 2021 (unaudited)      13,899   51,596   14,762   (6,517)  8,932   42,627   (73,914)  29,210   217,634   8,277   (252,142)  54,364 

 

 

For the period ended March 31, 2020

(unaudited)

  Note Share capital Share premium Warrant reserve Treasury shares Share based payment reserve Merger reserve Reverse acquisition reserve Equity component of convertible notes Other distributable reserves Currency translation reserve Accumulated deficit Total
       US$’000   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000 
Balance at January 1, 2020 (audited)      11,918   2,422   29,523   (7,534)  3,190   42,627   (73,914)  29,210   217,634   7,920   (133,674)  129,322 
Loss for the period                                    (28,897)  (28,897)
Foreign exchange translation reserve                                 (13)     (13)
Total comprehensive loss                                 (13)  (28,897)  (28,910)
Transactions with owners                                                    
Share based payment expense  4               745                     745 
Share based payment expense – Lapsed                  (2)                 2    
Total transactions with owners                  743                  2   745 
Balance at March 31, 2020 (unaudited)      11,918   2,422   29,523   (7,534)  3,933   42,627   (73,914)  29,210   217,634   7,907   (162,569)  101,157 

 

 9 

 

1. General information

 

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.

 

As used herein, references to ‘‘we,’’ ‘‘us,’’ ‘‘Amryt’’ or the ‘‘Group’’ in these condensed consolidated interim financial statements shall mean Amryt Pharma plc and its global subsidiaries, collectively. References to the ‘‘Company’’ in these condensed consolidated interim financial statements shall mean Amryt Pharma plc.

 

Amryt Pharma plc is a company incorporated in England and Wales. The Company is listed on Nasdaq (ticker: AMYT) and the AIM market of the London Stock Exchange (ticker: AMYT).

 

Aegerion Pharmaceuticals, Inc. (“Aegerion”), a former subsidiary of Novelion Therapeutics Inc., is a rare and orphan disease company with a diversified offering of multiple commercial and development stage assets. The acquisition of Aegerion by Amryt in September 2019 has given Amryt an expanded commercial footprint to market two U.S. and EU approved products, lomitapide (Juxtapid (U.S.) / Lojuxta (EU)) and metreleptin (Myalept (U.S.) / Myalepta (EU)).

 

Amryt's lead development asset, Filsuvez®/Oleogel-S10, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder for which there is currently no treatment. Oleogel-S10 is currently an investigational product and has not received regulatory approval by the FDA or EMA. Filsuvez® has been selected as the brand name for the product. On September 20, 2019, Amryt registered Filsuvez® as the trademark name for Oleogel-S10 in the European Union. On February 18, 2020, Amryt also registered this trademark name in the United States and is in the process of registering the trademark in other key jurisdictions.

 

On July 8, 2020, Amryt listed on the NASDAQ Global Select Market under the symbol AMYT. The Ordinary Shares will continue to trade on the AIM market of the London Stock Exchange.

 

On August 11, 2020 Amryt announced that the Company gave Euronext Dublin (“Euronext”) notice of its intention to cancel the admission of the Company’s Ordinary Shares (‘Ordinary Shares”) to trading on the Euronext Growth Market ("Cancellation"). The last day of trading in Ordinary Shares on the Euronext Growth Market was September 8, 2020. The Cancellation applies only to the Euronext Growth Market and will have no effect on the Company’s American Depositary Shares (“ADSs”) which trade on the NASDAQ Global Select Market under the symbol AMYT or on Amryt’s Ordinary Shares trading on the AIM market of the London Stock Exchange.

 

 

 10 

 

2. Accounting policies

 

Basis of preparation

 

The condensed consolidated interim financial statements of the Group have been prepared in accordance with IAS 34 Interim Financial Reporting. They do not include all of the information required in annual financial statements in accordance with International Financial Reporting Standards (‘‘IFRS’’) and should be read in conjunction with the annual consolidated financial statements for the year ended December 31, 2020. Selected explanatory notes are included to explain events and transactions that are significant to an understanding of the Group’s financial position and performance since the last annual financial statements. The accounting policies used in the preparation of the interim financial information are the same as those used in the Group’s audited financial statements for the year ended December 31, 2020 and those which are expected to be used in the financial statements for the year ended December 31, 2021.

 

Results for the three-month period ended March 31, 2021 are not necessarily indicative of the results that may be expected for the financial year ending December 31, 2021.

 

Basis of going concern

 

Having considered the Group’s current financial position and cash flow projections, the Board of Directors believes that the Group will be able to continue in operational existence for at least the next 12 months from the date of approval of these condensed consolidated interim financial statements and that it is appropriate to continue to prepare the condensed consolidated interim financial statements on a going concern basis.

 

As part of their inquiries, the Board of Directors reviewed budgets, projected cash flows, and other relevant information for a period not less than 12 months from the date of approval of the condensed consolidated interim financial statements for the period ended March 31, 2021.

 

Basis of consolidation

 

The condensed consolidated interim financial statements comprise the financial statements of the Group for the period ended March 31, 2021. Subsidiaries are entities controlled by the Company. Where the Company has control over an investee, it is classified as a subsidiary. The Company controls an investee if all three of the following elements are present: power over an investee, exposure or rights to variable returns from its involvement with the investee and the ability to use its power to affect those variable returns. Control is reassessed whenever facts and circumstances indicate that there may be a change in any of these elements of control.

 

Subsidiaries are fully consolidated from the date that control commences until the date that control ceases. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. Intergroup balances and any unrealized gains or losses, income or expenses arising from intergroup transactions are eliminated in preparing the condensed consolidated interim financial statements.

 

Presentation of balances

 

The condensed consolidated interim financial statements are presented in U.S. dollars (‘‘US$’’), rounded to the nearest thousand, which is the functional currency of the Company and presentation currency of the Group.

 

 11 

 

The following table discloses the major exchange rates of those currencies other than the functional currency of US$ that are utilized by the Group:

Foreign currency units to 1 US$     £   CHF   SEK   NOK   DKK 
Average period to March 31, 2021 (unaudited)  0.8292   0.7253   0.9043   8.3868   8.5171   6.1669 
At March 31, 2021 (unaudited)  0.8519   0.7274   0.9414   8.7214   8.5547   6.3351 

 

Foreign currency units to 1 US$     £   CHF   SEK   NOK   DKK 
Average period to December 31, 2020 (audited)  0.8777   0.7799   0.9391   9.2135   9.4206   6.5432 
At December 31, 2020 (audited)  0.8141   0.7365   0.8829   8.1885   8.5671   6.0570 

 

Foreign currency units to 1 US$     £   CHF   SEK   NOK   DKK 
Average period to March 31, 2020 (unaudited)  0.9068   0.7809   0.9679   9.6618   9.4731   6.7750 
At March 31, 2020 (unaudited)  0.9043   0.8068   0.9570   9.9977   10.5721   6.7517 

 

(€ = Euro; £ = Pounds Sterling, CHF = Swiss Franc, SEK = Swedish Kroner, NOK = Norwegian Kroner, DKK = Danish Kroner)

 

Changes in accounting policies and disclosures

 

There are no new standards and amendments to IFRS effective as of January 1, 2021 that are relevant to the Group.

 

Critical accounting judgements and key sources of estimation uncertainty

 

In preparing these condensed consolidated interim financial statements in conformity with IFRS management is required to make judgements, estimates and assumptions that affect the application of policies and amounts reported in the condensed consolidated interim financial statements and accompanying notes. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

 

The significant estimates, assumptions or judgements, applied in the condensed consolidated interim financial statements were the same as those applied in the Group’s audited financial statements for the year ended December 31, 2020.

 

Principal accounting policies

 

The condensed consolidated interim financial statements have been prepared in accordance with the accounting policies adopted in the Group’s audited financial statements for the year ended December 31, 2020.

 

 12 

 

 

3. Segment information

 

The Group is a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases.

 

The Group currently operates as one business segment, pharmaceuticals, and is focused on the development and commercialization of two commercial products and two development products. The Group derives its revenues primarily from one source, being the pharmaceutical sector with high unmet medical need.

 

The Group’s Chief Executive Officer, Joseph Wiley, is currently the Company’s chief operating decision maker (‘‘CODM’’). The Group does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Group does not accumulate discrete financial information with respect to separate service lines and does not have separate reportable segments.

 

The following table summarizes total revenues from external customers by product and by geographic region, based on the location of the customer.

  Three months ended March 31, 2021 (unaudited)
  U.S. EMEA Other Total
   US$’000   US$’000   US$’000   US$’000 
Metreleptin  16,239   12,971   750   29,960 
Lomitapide  8,324   7,440   2,420   18,184 
Other     223   65   288 
Total revenue  24,563   20,634   3,235   48,432 

 

  Three months ended March 31, 2020 (unaudited)
  U.S. EMEA Other Total
   US$’000   US$’000   US$’000   US$’000 
Metreleptin  14,914   8,628   3,385   26,927 
Lomitapide  9,470   5,233   2,718   17,421 
Other     226      226 
Total revenue  24,384   14,087   6,103   44,574 

 

Major Customers

 

For the three months ended March 31, 2021, one customer accounted for 51%, respectively, of the Group’s net revenues (2020: 55%, respectively) and accounted for 46% of the Group’s March 31, 2021 accounts receivable balance (December 31, 2020: 42%).

 

4. Share based payments

 

Under the terms of the Company’s Employee Share Option Plan, options to purchase 26,919,292 shares were outstanding at March 31, 2021. Under the terms of this plan, options are granted to officers, consultants and employees of the Group at the discretion of the Remuneration Committee. A total of 8,465,644 share options were granted to non-executive directors and employees in the three-month period ended March 31, 2021. For the year ended December 31, 2020, a total of 4,432,000 share options were granted to directors and employees.

 

 13 

 

 

The terms and conditions of the grants are as follows, whereby all options are settled by physical delivery of shares:

 

Vesting conditions

The employee share options vest following a period of service by the officer or employee. The required period of service is determined by the Remuneration Committee at the date of grant of the options (usually the date of approval by the Remuneration Committee) and it is generally over a three-year period. There are no market conditions associated with the share option vesting periods.

 

Contractual life

The term of an option is determined by the Remuneration Committee provided that the term may not exceed a period of seven to ten years from the date of grant. All options will terminate 90 days after termination of the option holder’s employment, service or consultancy with the Group except where a longer period is approved by the Board of Directors. Under certain circumstances involving a change in control of the Group, each option will automatically accelerate and become exercisable in full as of a date specified by the Board of Directors.

 

Outstanding warrants at March 31, 2021 consisted of 8,966,520 zero cost warrants (December 31, 2020: 8,966,520) with no expiration date that were issued to Aegerion creditors in connection with the acquisition of Aegerion. The remaining warrants consisting of 62,153 warrants (December 31, 2020: 345,542) were issued in connection with the admission to the AIM in 2016 and have since lapsed in April 2021.

 

The number and weighted average exercise price (in Sterling pence) of share options and warrants per ordinary share is as follows:

  Share Options Warrants
   Units   Weighted average exercise price (Sterling pence)   Units   Weighted average exercise price (Sterling pence) 
Balance at 1 January 2020  14,481,720   116.00p  17,541,815   0.03p
Granted  4,432,000   144.76p      
Lapsed  (87,119)  113.42p      
Exercised  (72,953)  120.72p  (8,229,753)   
Outstanding at 31 December 2020 (audited)  18,753,648   122.79p  9,312,062   0.05p
Exercisable at 31 December 2020 (audited)  5,866,152   114.24p  9,312,062   0.05p
                 
Balance at 1 January 2021  18,753,648   122.79p  9,312,062   0.05p
Granted  8,465,644   201.17p      
Lapsed            
Exercised  (300,000)  93.72p  (283,389)  1.44p
Outstanding at 31 March 2021 (unaudited)  26,919,292   147.77p  9,028,673   0.01p
Exercisable at 31 March 2021 (unaudited)  6,237,902   116.25p  9,028,673   0.01p

 

 

 14 

 

Fair value is estimated at the date of grant using the Black-Scholes pricing model, taking into account the terms and conditions attached to the grant. The following are the inputs to the model for the equity instruments granted during the period:

 

  

March 31, 2021

Options Inputs (unaudited)

 

March 31, 2021

Warrant Inputs (unaudited)

 

December 31, 2020

Options Inputs (audited)

 

December 31, 2020

Warrant Inputs (audited)

Days to Expiration  2,555      2,555    
Volatility  37%     33%-37%    
Risk free interest rate  0.77%     0.39%-0.46%    
Share price at grant  201.2p     123.5p–178.9p    

 

In the three months ended March 31, 2021, a total of 8,465,644 share options exercisable at a weighted average price of £2.012 were granted. The fair value of share options granted in the three months ended March 31, 2021 was £17,030,000/US$23,479,000.

 

The share options outstanding as at March 31, 2021 have a weighted remaining contractual life of 5.78 years with exercise prices ranging from £0.76 to £2.012.

 

The 2016 warrants outstanding as at March 31, 2021 have since lapsed in April 2021.

 

Restricted Share Units

Under the terms of the Company’s Employee Share Option Plan, restricted share units (“RSUs”) to purchase 1,834,090 shares were outstanding at March 31, 2021. Under the terms of this plan, RSUs are granted to officers, consultants and employees of the Group at the discretion of the Remuneration Committee. For the period ended March 31, 2021, a total of 293,180 RSUs were granted to employees of the company. For the year ended December 31, 2020, a total of 1,556,960 RSUs were granted to employees of the company. The fair value of the RSUs is based on the share price at the date of grant, with the expense spread over the vesting period. The fair value of RSUs granted in the period ended March 31, 2021 was US$861,000. At March 31,2021, the total RSUs granted to date have a weighted remaining contractual life of 2.45 years. The following table summarizes the RSU activity for the period:

 

  RSUs
  Unit Weighted average fair value (US$)
Balance at January 1, 2021  1,549,910  $2.35 
Granted  293,180  $2.80 
Lapsed  (9,000) $2.32 
Exercised      
Outstanding at March 31, 2021  1,834,090  $2.43 

 

The value of share options and RSU’s charged to the Condensed Consolidated Statement of Comprehensive Loss during the period is as follows:

  

Three months ended

March 31,

  

2021

(unaudited)

 

2020

(unaudited)

   US$’000   US$’000 
Share option expense  879   745 
RSU expense  384    
Total share option expense  1,263   745 

 

 

 15 

 

5. Business combinations and asset acquisitions

 

Acquisition of Aegerion Pharmaceuticals

 

On May 20, 2019, Amryt entered into a Restructuring Support Agreement (as subsequently amended on June 12, 2019) and Plan Funding Agreement pursuant to which, among other matters, Amryt agreed to the acquisition of Aegerion Pharmaceuticals, Inc. (‘‘Aegerion’’), a former wholly-owned subsidiary of Novelion Therapeutics Inc. (‘‘Novelion’’). On May 20, 2019, Aegerion and its U.S. subsidiary, Aegerion Pharmaceuticals Holdings, Inc., filed voluntary petitions under Chapter 11 of Title 11 of the U.S. Code in the Bankruptcy Court. On September 24, 2019, Amryt completed the acquisition of Aegerion. Amryt acquired Aegerion upon its emergence from bankruptcy in an exchange for ordinary shares and zero cost warrants in Amryt. Amryt issued 85,092,423 effective shares at US$1.793 per share, which is made up of 77,027,423 ordinary shares and 8,065,000 zero cost warrants, to acquire Aegerion for a value of US$152,615,000.

 

The Company believes that the acquisition of Aegerion will enable the Group to advance the Group’s ambition to create a global leader in rare and orphan diseases with a diversified offering of multiple development-stage and commercial assets and provides it with scale to support further growth.

 

As part of the acquisition of Aegerion, it was agreed, for certain Aegerion creditors who wished to restrict their percentage share interest in Amryt’s issued share capital, to issue to the relevant Aegerion creditor, as an alternative to Amryt’s ordinary shares, an equivalent number of new zero cost warrants to subscribe for Amryt’s ordinary shares to be constituted on the terms of the zero cost warrant.

 

Relevant Aegerion creditors are entitled at any time to exercise the zero cost warrants, at which point in time, the Company would issue to that Aegerion creditor the relevant number of fully paid ordinary shares in return for the exercise of the zero cost warrants. Each zero cost warrant entitles the holder thereof to subscribe for one ordinary share. The zero cost warrants constitute the Company’s direct and unsecured obligations and rank pari passu and without any preference among themselves (save for any obligations to be preferred by law) at least equally with the Company’s other present and future unsecured and unsubordinated obligations. The zero cost warrants are not transferable except with the Company’s prior written consent.

 

During the three months ended March 31, 2021, the Group incurred no additional acquisition and restructuring related costs relating to external legal fees, advisory fees, due diligence costs and severance costs (March 31, 2020: US$853,000). These costs were included in operating costs in the Condensed Consolidated Statement of Comprehensive loss.

 

Contingent Value Rights

 

Related to the transaction, Amryt issued Contingent Value Rights (‘‘CVRs’’) pursuant to which up to US$85,000,000 may become payable to Amryt’s shareholders and optionholders, who were on the register prior to the completion of the acquisition on September 20, 2019, if certain approval and revenue milestones are met in relation Oleogel-S10, Amryt’s lead product candidate. If any such milestone is achieved, Amryt may elect to pay the holders of CVRs by the issue of Amryt shares or loan notes. If Amryt elects to issue Loan Notes to holders of CVRs, it will settle such loan notes in cash 120 days after their issue. If none of the milestones are achieved, scheme shareholders and optionholders will not receive any additional consideration under the terms of the CVRs. In these circumstances, the value of each CVR would be zero.

 

 16 

 

The terms of the CVRs are as follows:

·The total CVR payable is up to US$85,000,000
 ·This is divided into three milestones which are related to the success of Oleogel-S10 (the Group’s lead development asset)

 

·FDA approval
oUS$35,000,000 upon FDA approval
o100% of the amount due if approval is obtained before December 31, 2021, with a sliding scale on a linear basis to zero if before July 1, 2022

 

·EMA approval
oUS$15,000,000 upon EMA approval
o100% of the amount due if approval is obtained before December 31, 2021, with a sliding scale on a linear basis to zero if before July 1, 2022

 

·Revenue targets
oUS$35,000,000 upon Oleogel-S10 revenues exceeding US$75,000,000 in any 12-month period prior to June 30, 2024

 

·Payment can at the Board’s discretion be in the form of either:
o120-day loan notes (effectively cash), or
oShares valued using the 30 day / 45-day VWAP.

 

The CVRs were contingent on the successful completion of the acquisition and, accordingly, have been based on fair value as at September 24, 2019. The CVRs have been classified as a financial liability in the Condensed Consolidated Statement of Financial Position. Given that CVRs were issued to legacy Amryt shareholders in their capacity as owners of the identified acquirer as opposed to the seller in the transaction, management concluded that the most appropriate classification would be to recognize the CVR as a distribution on consolidation instead of goodwill.

 

Measurement of CVRs

 

As at March 31, 2021, the carrying value of the CVRs was US$63,180,000 (December 31, 2020: US$61,417,000). The value of the potential payout was calculated using the probability-weighted expected returns method. Using this method, the potential payment amounts were multiplied by the probability of achievement and discounted to present value. The probability adjusted present values took into account published orphan drug research data and statistics which were adjusted by management to reflect the specific circumstances applicable to the type of product acquired in the Amryt GmbH transaction. The market-based probability chance of success is based on market benchmarks for orphan drugs was estimated at 89% in the period ended March 31, 2021 (2020: 89%). Discount rates of 10% and 16.5%, as applicable, were used in the calculation of the present value of the estimated contractual cash flows for the period ended March 31, 2021 (December 31, 2020: 10% and 16.5%). Management was required to make certain estimates and assumptions in relation to revenue forecasts, timing of revenues and probability of achievement of commercialization of Oleogel-S10. However, management notes that, due to issues outside their control (i.e. regulatory requirements and the commercial success of the product), the timing of when such revenue targets may occur may change. Such changes may have a material impact on the assessment of the expected cash flows of the CVRs.

 

Amryt reviews the expected cash flows on a regular basis as the discount on initial recognition is being unwound as financing expenses in the Condensed Consolidated Statement of Comprehensive Loss over the life of the obligation. It is reviewed on a quarterly basis and the appropriate finance charge is booked in the Condensed Consolidated Statement of Comprehensive Loss on a quarterly basis. The Group received positive topline data from the phase 3 EASE trial of Oleogel-S10 in September 2020. The Group recently submitted applications for approval from the FDA and the EMA.

 

 17 

 

The total non-cash finance charge recognized in the Condensed Consolidated Statement of Comprehensive Loss for the three months ended March 31, 2021 is US$1,763,000 (March 31, 2020: US$1,448,000).

 

Acquisition of Amryt GmbH (previously ‘‘Birken’’)

 

Amryt DAC signed a conditional share purchase agreement to acquire Amryt GmbH on October 16, 2015 (‘‘Amryt GmbH SPA’’). The Amryt GmbH SPA was completed on April 18, 2016 with Amryt DAC acquiring the entire issued share capital of Amryt GmbH. The consideration included contingent consideration comprising milestone payments and sales royalties as follows:

 

·Milestone payments of:
o€10,000,000 on receipt of first marketing approval by the EMA of Episalvan, paid on the completion date (April 18, 2016);
oEither (i) €5,000,000 once net ex-factory sales of Episalvan have been at least €100,000 or (ii) if no commercial sales are made within 24 months of EMA first marketing approval (being January 14, 2016), €2,000,000 24 months after receipt of such approval, which was paid in January 2018, and €3,000,000 following the first commercial sale of Episalvan;
o€10,000,000 on receipt of marketing approval by the EMA or FDA of a pharmaceutical product containing Betulin as its API for the treatment of EB;
 o€10,000,000 once net ex-factory sales/net revenue of Oleogel S-10 first exceed €50,000,000 in any calendar year;
 o€15,000,000 once net ex-factory sales/ net revenue of Oleogel S-10 first exceed €100,000,000 in any calendar year;

·Cash consideration of €150,000, due and paid on the completion date (April 18, 2016); and
·Royalties of 9% on sales of Oleogel-S10 products for 10 years from first commercial sale.

 

Fair Value Measurement of Contingent Consideration

 

As at March 31, 2021, the fair value of the contingent consideration was estimated to be US$85,884,000 (December 31, 2020: US$86,906,000). The fair value of the royalty payments was determined using probability weighted revenue forecasts and the fair value of the milestone payments was determined using probability adjusted present values (see Note 14, Fair value measurement and financial risk management, for fair value hierarchy applied and impact of key unobservable impact data). The probability adjusted present values took into account published orphan drug research data and statistics which were adjusted by management to reflect the specific circumstances applicable to the type of product acquired in the Amryt GmbH transaction. The market-based probability chance of success is based on market benchmarks for orphan drugs was estimated at 89% for the period ended March 31, 2021 (December 31, 2020: 89%) following the positive results from our phase 3 EASE trial of Oleogel-S10 earlier in the year. A discount rate of 14.4% was used in the calculation of the fair value of the contingent consideration for the three months ended March 31, 2021 (December 31, 2020: 14.4%).

 

The Group received positive top line results from the phase 3 EASE trial of Oleogel-S10 in September 2020, and the Group recently submitted applications for approval from the FDA and the EMA.

 

 18 

 

Amryt reviews the contingent consideration on a regular basis as the probability adjusted fair values are being unwound as financing expenses in the Condensed Consolidated Statement of Comprehensive Loss over the life of the obligation. The finance charge is being unwound as a financing expense in the Condensed Consolidated Statement of Comprehensive Loss on a quarterly basis.

 

The total non-cash finance charge recognized in the Condensed Consolidated Statement of Comprehensive Loss for the three months ended March 31, 2021 is US$2,874,000 (March 31, 2020: US$2,906,000).

 

 

6. Loss per share - basic and diluted

 

The weighted average number of shares in the loss per share (‘‘LPS’’) calculation, reflects the weighted average total actual shares of Amryt Pharma plc in issue at March 31, 2021.

 

Issued share capital - ordinary shares of £0.06 each

 

   Number of shares   Weighted average shares 
March 31, 2021 (unaudited)  179,384,982   178,937,717 
March 31, 2020 (unaudited)  154,498,887   154,498,887 

 

The calculation of loss per share is based on the following:

  Three months ended March 31
  2021 (unaudited) 

2020

(unaudited)

Loss after tax attributable to equity holders of the Company (US$’000)  (16,537)  (28,897)
Weighted average number of ordinary shares in issue  178,937,717   154,498,887 
Fully diluted average number of ordinary shares in issue  178,937,717   154,498,887 
Basic and diluted loss per share (US$)  (0.09)  (0.19)

 

Where a loss has occurred, basic and diluted LPS are the same because the outstanding share options and warrants are anti-dilutive. Accordingly, diluted LPS equals the basic LPS. The share options and warrants outstanding as at March 31, 2021 totaled 35,947,965 (March 31, 2020: 28,065,710) and are potentially dilutive.

 

 

 19 

 

7. Intangible assets and goodwill

 

The following table summarizes the Group’s intangible assets and goodwill:

  Developed technology - metreleptin Developed technology - lomitapide In process R&D Other intangible assets Total intangible assets Goodwill
   US$’000   US$’000   US$’000   US$’000   US$’000   US$’000 
Cost                        
At January 1, 2020 (audited)  176,000   123,000   54,261   701   353,962   19,131 
Additions           372   372    
Acquired assets        591      591    
Disposals           (246)  (246)   
Foreign exchange movement        5,276   39   5,315    
At December 31, 2020 (audited)  176,000   123,000   60,128   866   359,994   19,131 
Additions           416   416    
Foreign exchange movement        (2,667)  (35)  (2,702)   
At March 31, 2021 (unaudited)  176,000   123,000   57,461   1,247   357,708   19,131 
                         
Accumulated amortization                        
At January 1, 2020 (audited)  7,314   4,143      178   11,635    
Amortization charge  27,429   15,537      202   43,168    
Accumulated amortization on disposals           (246)  (246)   
Foreign exchange movement           68   68    
At December 31, 2020 (audited)  34,743   19,680      202   54,625    
Amortization charge  6,857   3,884      31   10,772    
Foreign exchange movement           (4)  (4)   
At March 31, 2021 (unaudited)  41,600   23,564      229   65,393    
                         
Net book value                        
At December 31, 2020 (audited)  141,257   103,320   60,128   664   305,369   19,131 
At March 31, 2021 (unaudited)  134,400   99,436   57,461   1,018   292,315   19,131 

 

Developed technology on commercially marketed products

 

In connection with the acquisition of Aegerion in September 2019, the Group acquired developed technology, metreleptin and lomitapide. These intangible assets are amortized over their estimated useful lives and the remaining useful lives for metreleptin and lomitapide are approximately 4.9 and 6.4 years, respectively, as of March 31, 2021 (December 31, 2020: 5.2 and 6.7 years, respectively). 

 

In-process R&D

 

As a result of the acquisition of Amryt GmbH, in 2016, the Group recognized in-process R&D costs of €52,515,000 which is related to the Group’s lead development asset, Oleogel-S10.

 

 20 

 

 

Goodwill

 

During 2019, the Group completed the acquisition of Aegerion, which resulted in aggregate goodwill of US$19,131,000.

 

The Group reviews events or changes in circumstances that may indicate a triggering event for impairment. Management applied its judgment in determining that there were no events or changes in circumstances causing any impairment triggers as of March 31, 2021. As such there was no impairment charge recorded during the three months ended March 31, 2021.

 

 

8. Trade and other receivables

  As at
  

March 31, 2021

(unaudited)

 

December 31, 2020

(audited)

   US$’000   US$’000 
Trade receivables  37,224   33,057 
Accrued income and other debtors  6,220   8,423 
VAT recoverable  519   1,705 
Trade and other receivables  43,963   43,185 

 

9. Cash and cash equivalents

  As at
  

March 31, 2020

(unaudited)

 

December 31, 2020

(audited)

   US$’000   US$’000 
Cash at bank available on demand  118,522   118,575 
Restricted cash  29   223 
Total cash and cash equivalents  118,551   118,798 

 

Cash and cash equivalents include cash at bank available on demand and restricted cash.

 

At March 31, 2021 and December 31, 2020, there was US$29,000 and US$223,000 of restricted cash, respectively. The balance at December 31, 2020 includes a deposit on a company credit card facility for an amount of US$150,000. This was reduced to nil as at March 31, 2021. Additionally, there was US$29,000 held by a third-party distributor at March 31, 2021 (December 31, 2020: US$73,000.

 

 

 21 

 

10. Share capital and reserves

 

Details of the number of issued ordinary shares with a nominal value of Sterling 6 pence (2020: 6 pence) each are in the table below.

 

  Ordinary shares Treasury shares Total
At January 1, 2020  154,498,887   4,864,656   159,363,543 
Issue of shares in exchange for warrants  8,229,753      8,229,753 
Issue of shares in equity fund raises  16,000,000      16,000,000 
Issue of treasury shares for share options exercised  72,953   (72,953)   
At December 31, 2020 (audited)  178,801,593   4,791,703   183,593,296 
Issue of treasury shares in exchange for warrants  283,389   (283,389)   
Issue of treasury shares for share options exercised  300,000   (300,000)   
At March 31, 2021 (unaudited)  179,384,982   4,208,314   183,593,296 

 

The components of equity are detailed in the Condensed Consolidated Statement of Changes in Equity and described in more detail below.

 

The total number of ordinary shares issued at March 31, 2021 of 183,593,296 (December 31, 2020: 183,593,296), includes treasury shares of 4,208,314 (December 31, 2020: 4,791,703).

 

In December 2020, the Company issued 3,200,000 American Deposit Shares (“ADSs”), each representing five ordinary shares, as part of a US$40,000,000 private placement equity raise to existing and new shareholders.

 

On March 11, 2021, the Company issued 300,000 ordinary shares from treasury shares following the exercise of share options. On March 11, 2021, the Company issued 283,389 ordinary shares from treasury shares in exchange for certain warrants. The Company issued 4,000,000 and 4,229,753 ordinary shares on July 15, 2020 and September 22, 2020, respectively, in exchange for certain warrants.

 

Share Capital

Share capital represents the cumulative par value arising upon issue of ordinary shares of Sterling 6 pence each.

The ordinary shares have the right to receive notice of, attend and vote at general meetings and participate in the profits of the Company.

 

Share Premium

Share premium represents the consideration that has been received in excess of the nominal value on issue of share capital net of issue costs and transfers to distributable reserves.

 

Warrant reserve

The warrant reserve represents zero cost warrants issued as part of the equity raise on September 24, 2019 net of issue costs apportioned to warrants issued and additional warrants issued to certain shareholders on November 14, 2019. Each warrant entitles the holder to subscribe for one ordinary share at zero cost. The Company issued 4,000,000 and 4,229,753 ordinary shares on July 15, 2020 and September 22, 2020, respectively, in exchange for certain warrants.

 22 

 

 

Treasury Shares

In October 2020, the Company issued 72,953 ordinary shares from treasury shares following the exercise of share options. In March 2021, the Company issued a total of 583,389 ordinary shares from treasury shares, 300,000 ordinary shares relating to the exercise of share options and 283,389 ordinary shares following the exchange of certain warrants.

 

Share based payment reserve

Share based payment reserve relates to the charge for share based payments in accordance with IFRS 2. In March 2021, the Company issued 283,389 ordinary shares in exchange for certain warrants.

 

Merger reserve

The merger reserve was created on the acquisition of Amryt DAC by Amryt Pharma plc in April 2016. Ordinary shares in Amryt Pharma plc were issued to acquire the entire issued share capital of Amryt DAC. Under section 612 of the UK Companies Act 2006, the premium on these shares has been included in a merger reserve.

 

Reverse acquisition reserve

The reverse acquisition reserve arose during the period ended December 31, 2016 in respect of the reverse acquisition of Amryt Pharma plc by Amryt DAC. Since the shareholders of Amryt DAC became the majority shareholders of the enlarged Group, the acquisition is accounted for as though there is a continuation of Amryt DAC’s financial statements. The reverse acquisition reserve is created to maintain the equity structure of Amryt Pharma plc in compliance with UK company law.

 

Equity component of convertible notes

The equity component of convertible notes represents the equity component of the US$125,000,000 convertible debt and is measured by determining the residual of the fair value of the instrument less the estimated fair value of the liability component. The equity component is recognized in equity and is not subsequently remeasured.

 

Currency translation reserve

The currency translation reserve arises on the retranslation of non-U.S. dollar denominated foreign subsidiaries.

 

Accumulated deficit

Accumulated deficit represents losses accumulated in previous periods and the current year.

 

 

 23 

 

11. Long term loan

  As at
  

March 31, 2021

(unaudited)

 

December 31, 2020

(audited)

   US$’000   US$’000 
Long term loan principal  89,472   88,037 
Unamortized debt issuance costs  (703)  (735)
Long term loan  88,769   87,302 

 

As part of the acquisition of Aegerion on September 24, 2019, Aegerion entered into a new U.S. dollar denominated US$81,021,000 secured term loan debt facility (‘‘Term Loan’’) with various lenders. The Term Loan is made up of a US$54,469,000 loan that was in place prior to the acquisition which was refinanced as part of the acquisition and a US$26,552,000 additional loan that was drawn down on September 24, 2019. The Term Loan has a five-year term from the date of the draw down, September 24, 2019 and matures on September 24, 2024. Under the Term Loan, interest will be payable at the option of the Group at the rate of 11% per annum paid in cash on a quarterly basis or at a rate of 6.5% paid in cash plus 6.5% paid in kind that will be paid when the principal is repaid, which rolls up and is included in the principal balance outstanding, on a quarterly basis. Unpaid accrued interest of US$1,431,000 as at March 31, 2021 is recognized in current liabilities with trade and other payables (December 31, 2020: $1,439,000). The Term Loan may be prepaid, in whole or in part, by Aegerion at any time subject to payment of an exit fee, which depending on the stage of the loan term, ranges from 5.00% to 0.00% of the principal then outstanding on the Term Loan.

 

In connection with the Term Loan, the Group incurred approximately US$870,000 of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees. These costs are being amortized over the expected life of the loan using the effective interest method.

 

The Term Loan is guaranteed by Amryt and certain subsidiaries of the Group. In connection with the loan agreement, fixed and floating charges have been placed on property and undertakings of Amryt and certain subsidiaries of the Group.

 

The Term Loan agreement includes affirmative and negative covenants, including prohibitions on the incurrence of additional indebtedness, granting of liens, certain asset dispositions, investments, and restricted payments, in each case, subject to certain exceptions set forth in the Loan Agreement. The Term Loan agreement also includes customary events of default for a transaction of this type and includes (i) a cross-default to the occurrence of any event of default under material indebtedness of Aegerion and certain subsidiaries of the Group and Amryt, including the convertible notes, and (ii) Amryt or any of its subsidiaries being subject to bankruptcy or other insolvency proceedings. Upon the occurrence of an event of default, the lenders may declare all of the outstanding Term Loan and other obligations under the Term Loan agreement to be immediately due and payable and exercise all rights and remedies available to the lenders under the Term Loan agreement and related documentation. There have been no events of default or breaches of the covenants occurring for the three months ended March 31, 2021 (December 31, 2020: no events).

 

 

 24 

 

12. Convertible notes

  Total
   US$’000 
At January 1, 2020  96,856 
Accreted interest  4,230 
At December 31, 2020 (audited)  101,086 
Accreted interest  1,130 
At March 31, 2021 (unaudited)  102,216 

 

As part of the acquisition, Aegerion issued convertible notes with an aggregate principal amount of US$125,000,000 to Aegerion creditors.

 

The convertible notes are senior unsecured obligations and bear interest at a rate of 5.0% per year, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on April 1, 2020. The convertible notes will mature on April 1, 2025, unless earlier repurchased or converted.

 

The convertible notes are convertible into Amryt’s ordinary shares at a conversion rate of 386.75 ordinary shares per US$1,000 principal amount of the convertible notes. If the holders elect to convert the convertible notes, Aegerion can settle the conversion of the convertible notes through payment or delivery of cash, common shares, or a combination of cash and common shares, at its discretion. As a result of the conversion feature in the convertible notes, the convertible notes were assessed to have both a debt and an equity component. The two components were assessed separately and classified as a financial liability and equity instrument. The financial liability component was measured at fair value based on the discounted cash flows expected over the expected term of the notes using a discount rate based on a market interest rate that a similar debt instrument without a conversion feature would be subject to. Refer to Note 10, Share capital and reserves, for further details on the equity component of the convertible notes.

 

From September 24, 2019 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their convertible notes, in multiples of US$1,000 principal amount, at the option of the holder.

 

The indenture does not contain any financial covenants or restrict the Group’s ability to repurchase securities, pay dividends or make restricted payments in the event of a transaction that substantially increases the Group’s level of indebtedness in certain circumstances.

 

The indenture contains customary terms and covenants and events of default. If an event of default (other than certain events of bankruptcy, insolvency or reorganization involving Aegerion, Amryt and certain subsidiaries of the Group) occurs and is continuing, the trustee by notice to Aegerion, or the holders of at least 25% in principal amount of the outstanding convertible notes by written notice to Aegerion and the trustee, may declare 100% of the principal of and accrued and unpaid interest, if any, on all of the convertible notes to be due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately. Upon the occurrence of certain events of bankruptcy, insolvency or reorganization involving Aegerion, 100% of the principal and accrued and unpaid interest, if any, on the convertible notes will become due and payable automatically. Notwithstanding the foregoing, the indenture provides that, upon Aegerion’s election, and for up to 180 days, the sole remedy for an event of default relating to certain failures by Aegerion to comply with certain reporting covenants in the indenture consists exclusively of the right to receive additional interest on the convertible notes. There have been no events of default or breaches of the covenants occurring for the period ended March 31, 2021 (2020: no events).

 25 

 

 

13. Provisions and other liabilities

  As at
  

March 31, 2021

(unaudited)

 

December 31, 2020

(audited)

   US$’000   US$’000 
Non-current liabilities        
Provisions and other liabilities  22,292   21,382 
Leases due greater than 1 year  4,357   4,569 
   26,649   25,951 
Current liabilities        
Provisions and other liabilities  6,000   9,976 
Leases due less than 1 year  967   963 
   6,967   10,939 
Total provisions and other liabilities  33,616   36,890 

 

Legal matters

 

Prior to the acquisition of Aegerion by Amryt, Aegerion entered into settlement agreements with governmental entities including the Department of Justice (‘‘DOJ’’) and the FDA in connection with Juxtapid investigations. The settlement agreements require Aegerion to pay specified fines and engage in regulatory compliance efforts. Subsequent to the acquisition, Aegerion made US$23,036,000 of settlement payments, including interest. The settlements have been paid in full with the last payment completed in Q1 2021. There is no current liability recognized as at March 31, 2021 (December 31, 2020: US$3,976,000). There is no non-current liability at March 31, 2021 (December 31, 2020: nil).

 

Other matters

 

The Group recognizes a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that it can reasonably estimate the amount of the loss. The Group reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and the Group’s views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Group’s liability accrual would be recorded in the period in which such determination is made. At March 31, 2021 the Group had recognized liabilities of US$6,000,000 in relation to ongoing legal matters (December 31, 2020 US$6,000,000).

 

 

 26 

 

14. Fair value measurement and financial risk management

 

Categories of financial instruments

  As at
  

March 31, 2021

(unaudited)

 

December 31, 2020

(audited)

   US$’000   US$’000 
Financial assets (all at amortized cost):        
Cash and cash equivalents  118,551   118,798 
Trade receivables  37,224   33,057 
Total financial assets  155,775   151,855 
         
Financial liabilities:        
At amortized cost        
Trade payables and accrued expenses  83,631   89,300 
Lease liabilities  5,324   5,532 
Other liabilities  22,292   25,358 
Convertible notes  102,216   101,086 
Long term loan  88,769   87,302 
Contingent value rights  63,180   61,417 
At fair value        
Contingent consideration  85,884   86,906 
Total financial liabilities  451,296   456,901 
Net  (295,521)  (305,046)

 

Financial instruments evaluated at fair value can be classified according to the following valuation hierarchy, which reflects the extent to which the fair value is observable:

·Level 1: fair value evaluations using prices listed on active markets (not adjusted) of identical assets or liabilities.
·Level 2: fair value evaluations using input data for the asset or liability that are either directly observable (as prices) or indirectly observable (derived from prices), but which do not constitute listed prices pursuant to Level 1.
·Level 3: fair value evaluations using input data for the asset or liability that are not based on observable market data (unobservable input data).

 

The contingent consideration has been valued using Level 3. The contingent consideration comprises:

·Contingent consideration relating to the acquisition of Amryt GmbH (see Note 5, Business combinations and asset acquisitions) that was measured at US$85,884,000 as at March 31, 2021 (December 31, 2020: US$86,906,000). The fair value comprises royalty payments which was determined using probability weighted revenue forecasts and the fair value of the milestones payments which was determined using probability adjusted present values. It also included a revision to the discount rate used, and revenue and costs forecasts have been amended to reflect management’s current expectations.

 

Impact of key unobservable input data

·An increase of 10% in estimated revenue forecasts would result in an increase to the fair value of US$6,009,000. A decrease would have the opposite effect.
·A 5% increase in the discount factor used would result in a decrease to the fair value of US$14,718,000. A decrease of 5% would result in an increase to the fair value of US$19,539,000.
·A six-month delay in the launch date for Oleogel-S10 would result in a decrease to the fair value of US$8,576,000.

 

 27 

 

15. Events after the reporting period

 

On May 5, 2021, Amryt announced that it had signed a definitive agreement to acquire Chiasma, Inc. (“Chiasma”) in an all-stock combination. The combined company will be a global leader in rare and orphan diseases with three on-market commercial products, a global commercial and operational footprint and a significant development pipeline of therapies with the financial flexibility to execute its growth plans. The transaction has been approved and recommended by the Boards of both Amryt and Chiasma.

 

Under the terms of the transaction, each share of Chiasma common stock issued and outstanding prior to the consummation of the transaction will be exchanged for 0.396 Amryt ADSs, each representing five Amryt ordinary shares. As of the close of trading on May 4, 2021 Amryt’s ordinary shares on AIM were £2.00 ($2.78) per share and Amryt’s ADS’s on Nasdaq were $12.95 (£9.31) per ADS.

 

There were no other significant events since the end of the reporting period.

 

 

 

 

 

 

 

 

28